KNSA Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

HAMILTON, Bermuda , Sept. 09, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that it will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16th, 2020 at 2:00 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at . A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s clinical-stage product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways that are implicated across a spectrum of diseases. For more information, please visit .

Every Second Counts!™ 



Kiniksa Investor and Media Contact

Mark Ragosa

(781) 430-8289

EN
09/09/2020

Underlying

KNSAKiniksa Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kiniksa Pharmaceuticals

 PRESS RELEASE
Free
KNSA Kiniksa Pharmac...

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results a...

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical...

October 28, 2025 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
KNSA KINIKSA PHARMACEUTICALS
10/28/25 October 28, 2025 1 EN
 PRESS RELEASE
Free
KNSA Kiniksa Pharmac...

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results...

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025 LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern Time to report its third quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at . Individuals interested in participating in the call via telephone may register . Upon registration, all telephone participants will re...

October 23, 2025 1 EN
 PRESS RELEASE
Free
KNSA Kiniksa Pharmac...

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL...

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, which includes recurrent pericarditis. KPL-387 is an independently developed monoclonal antibody that binds human interleukin...

October 17, 2025 1 EN
Wedbush Research
  • Wedbush Research
PHM PULTEGROUP INC.
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
ACRS ACLARIS THERAPEUTICS INC.
FRX_CN FENNEC PHARMACEUTICALS
TMHC TAYLOR MORRISON HOME CORPORATION
WVE WAVE LIFE SCIENCES
MHO M/I HOMES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
RCUS ARCUS BIOSCIENCES
KNSA KINIKSA PHARMACEUTICALS
IDYA IDEAYA BIOSCIENCES
BEAM BEAM THERAPEUTICS
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
NUVL NUVALENT INC
PRME PRIME MEDICINE INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
STUB STUBHUB HOLDINGS INC.
10/13/25 October 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch